<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1988-08-01" modified="2020-10-07" version="244">
<accession>P08047</accession>
<accession>E4Z9M7</accession>
<accession>G5E9M8</accession>
<accession>Q86TN8</accession>
<accession>Q9H3Q5</accession>
<accession>Q9NR51</accession>
<accession>Q9NY21</accession>
<accession>Q9NYE7</accession>
<name>SP1_HUMAN</name>
<protein>
<recommendedName>
<fullName>Transcription factor Sp1</fullName>
</recommendedName>
</protein>
<gene>
<name type="primary">SP1</name>
<name type="synonym">TSFP1</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="2011" name="Biochem. Biophys. Res. Commun." volume="412" first="86" last="91">
<title>Identification of a novel Sp1 splice variant as a strong transcriptional activator.</title>
<authorList>
<person name="Infantino V."/>
<person name="Convertini P."/>
<person name="Iacobazzi F."/>
<person name="Pisano I."/>
<person name="Scarcia P."/>
<person name="Iacobazzi V."/>
</authorList>
<dbReference type="PubMed" id="21798247"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2011.07.047"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2006" name="Nature" volume="440" first="346" last="351">
<title>The finished DNA sequence of human chromosome 12.</title>
<authorList>
<person name="Scherer S.E."/>
<person name="Muzny D.M."/>
<person name="Buhay C.J."/>
<person name="Chen R."/>
<person name="Cree A."/>
<person name="Ding Y."/>
<person name="Dugan-Rocha S."/>
<person name="Gill R."/>
<person name="Gunaratne P."/>
<person name="Harris R.A."/>
<person name="Hawes A.C."/>
<person name="Hernandez J."/>
<person name="Hodgson A.V."/>
<person name="Hume J."/>
<person name="Jackson A."/>
<person name="Khan Z.M."/>
<person name="Kovar-Smith C."/>
<person name="Lewis L.R."/>
<person name="Lozado R.J."/>
<person name="Metzker M.L."/>
<person name="Milosavljevic A."/>
<person name="Miner G.R."/>
<person name="Montgomery K.T."/>
<person name="Morgan M.B."/>
<person name="Nazareth L.V."/>
<person name="Scott G."/>
<person name="Sodergren E."/>
<person name="Song X.-Z."/>
<person name="Steffen D."/>
<person name="Lovering R.C."/>
<person name="Wheeler D.A."/>
<person name="Worley K.C."/>
<person name="Yuan Y."/>
<person name="Zhang Z."/>
<person name="Adams C.Q."/>
<person name="Ansari-Lari M.A."/>
<person name="Ayele M."/>
<person name="Brown M.J."/>
<person name="Chen G."/>
<person name="Chen Z."/>
<person name="Clerc-Blankenburg K.P."/>
<person name="Davis C."/>
<person name="Delgado O."/>
<person name="Dinh H.H."/>
<person name="Draper H."/>
<person name="Gonzalez-Garay M.L."/>
<person name="Havlak P."/>
<person name="Jackson L.R."/>
<person name="Jacob L.S."/>
<person name="Kelly S.H."/>
<person name="Li L."/>
<person name="Li Z."/>
<person name="Liu J."/>
<person name="Liu W."/>
<person name="Lu J."/>
<person name="Maheshwari M."/>
<person name="Nguyen B.-V."/>
<person name="Okwuonu G.O."/>
<person name="Pasternak S."/>
<person name="Perez L.M."/>
<person name="Plopper F.J.H."/>
<person name="Santibanez J."/>
<person name="Shen H."/>
<person name="Tabor P.E."/>
<person name="Verduzco D."/>
<person name="Waldron L."/>
<person name="Wang Q."/>
<person name="Williams G.A."/>
<person name="Zhang J."/>
<person name="Zhou J."/>
<person name="Allen C.C."/>
<person name="Amin A.G."/>
<person name="Anyalebechi V."/>
<person name="Bailey M."/>
<person name="Barbaria J.A."/>
<person name="Bimage K.E."/>
<person name="Bryant N.P."/>
<person name="Burch P.E."/>
<person name="Burkett C.E."/>
<person name="Burrell K.L."/>
<person name="Calderon E."/>
<person name="Cardenas V."/>
<person name="Carter K."/>
<person name="Casias K."/>
<person name="Cavazos I."/>
<person name="Cavazos S.R."/>
<person name="Ceasar H."/>
<person name="Chacko J."/>
<person name="Chan S.N."/>
<person name="Chavez D."/>
<person name="Christopoulos C."/>
<person name="Chu J."/>
<person name="Cockrell R."/>
<person name="Cox C.D."/>
<person name="Dang M."/>
<person name="Dathorne S.R."/>
<person name="David R."/>
<person name="Davis C.M."/>
<person name="Davy-Carroll L."/>
<person name="Deshazo D.R."/>
<person name="Donlin J.E."/>
<person name="D'Souza L."/>
<person name="Eaves K.A."/>
<person name="Egan A."/>
<person name="Emery-Cohen A.J."/>
<person name="Escotto M."/>
<person name="Flagg N."/>
<person name="Forbes L.D."/>
<person name="Gabisi A.M."/>
<person name="Garza M."/>
<person name="Hamilton C."/>
<person name="Henderson N."/>
<person name="Hernandez O."/>
<person name="Hines S."/>
<person name="Hogues M.E."/>
<person name="Huang M."/>
<person name="Idlebird D.G."/>
<person name="Johnson R."/>
<person name="Jolivet A."/>
<person name="Jones S."/>
<person name="Kagan R."/>
<person name="King L.M."/>
<person name="Leal B."/>
<person name="Lebow H."/>
<person name="Lee S."/>
<person name="LeVan J.M."/>
<person name="Lewis L.C."/>
<person name="London P."/>
<person name="Lorensuhewa L.M."/>
<person name="Loulseged H."/>
<person name="Lovett D.A."/>
<person name="Lucier A."/>
<person name="Lucier R.L."/>
<person name="Ma J."/>
<person name="Madu R.C."/>
<person name="Mapua P."/>
<person name="Martindale A.D."/>
<person name="Martinez E."/>
<person name="Massey E."/>
<person name="Mawhiney S."/>
<person name="Meador M.G."/>
<person name="Mendez S."/>
<person name="Mercado C."/>
<person name="Mercado I.C."/>
<person name="Merritt C.E."/>
<person name="Miner Z.L."/>
<person name="Minja E."/>
<person name="Mitchell T."/>
<person name="Mohabbat F."/>
<person name="Mohabbat K."/>
<person name="Montgomery B."/>
<person name="Moore N."/>
<person name="Morris S."/>
<person name="Munidasa M."/>
<person name="Ngo R.N."/>
<person name="Nguyen N.B."/>
<person name="Nickerson E."/>
<person name="Nwaokelemeh O.O."/>
<person name="Nwokenkwo S."/>
<person name="Obregon M."/>
<person name="Oguh M."/>
<person name="Oragunye N."/>
<person name="Oviedo R.J."/>
<person name="Parish B.J."/>
<person name="Parker D.N."/>
<person name="Parrish J."/>
<person name="Parks K.L."/>
<person name="Paul H.A."/>
<person name="Payton B.A."/>
<person name="Perez A."/>
<person name="Perrin W."/>
<person name="Pickens A."/>
<person name="Primus E.L."/>
<person name="Pu L.-L."/>
<person name="Puazo M."/>
<person name="Quiles M.M."/>
<person name="Quiroz J.B."/>
<person name="Rabata D."/>
<person name="Reeves K."/>
<person name="Ruiz S.J."/>
<person name="Shao H."/>
<person name="Sisson I."/>
<person name="Sonaike T."/>
<person name="Sorelle R.P."/>
<person name="Sutton A.E."/>
<person name="Svatek A.F."/>
<person name="Svetz L.A."/>
<person name="Tamerisa K.S."/>
<person name="Taylor T.R."/>
<person name="Teague B."/>
<person name="Thomas N."/>
<person name="Thorn R.D."/>
<person name="Trejos Z.Y."/>
<person name="Trevino B.K."/>
<person name="Ukegbu O.N."/>
<person name="Urban J.B."/>
<person name="Vasquez L.I."/>
<person name="Vera V.A."/>
<person name="Villasana D.M."/>
<person name="Wang L."/>
<person name="Ward-Moore S."/>
<person name="Warren J.T."/>
<person name="Wei X."/>
<person name="White F."/>
<person name="Williamson A.L."/>
<person name="Wleczyk R."/>
<person name="Wooden H.S."/>
<person name="Wooden S.H."/>
<person name="Yen J."/>
<person name="Yoon L."/>
<person name="Yoon V."/>
<person name="Zorrilla S.E."/>
<person name="Nelson D."/>
<person name="Kucherlapati R."/>
<person name="Weinstock G."/>
<person name="Gibbs R.A."/>
</authorList>
<dbReference type="PubMed" id="16541075"/>
<dbReference type="DOI" id="10.1038/nature04569"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="4">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Brain</tissue>
<tissue>Testis</tissue>
</source>
</reference>
<reference key="5">
<citation type="submission" date="2000-04" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Haggart M.H."/>
<person name="Ladurner A.G."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 4-785 (ISOFORM 1)</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="6">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="38067" last="38072">
<title>Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing.</title>
<authorList>
<person name="Takahara T."/>
<person name="Kanazu S."/>
<person name="Yanagisawa S."/>
<person name="Akanuma H."/>
</authorList>
<dbReference type="PubMed" id="10973950"/>
<dbReference type="DOI" id="10.1074/jbc.m002010200"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-558 (ISOFORM 1)</scope>
<scope>TRANS-SPLICING</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1987" name="Cell" volume="51" first="1079" last="1090">
<title>Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain.</title>
<authorList>
<person name="Kadonaga J.T."/>
<person name="Carner K.R."/>
<person name="Masiarz F.R."/>
<person name="Tjian R."/>
</authorList>
<dbReference type="PubMed" id="3319186"/>
<dbReference type="DOI" id="10.1016/0092-8674(87)90594-0"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 90-785 (ISOFORM 1/2)</scope>
<scope>PROTEIN SEQUENCE OF 359-375 AND 670-675</scope>
</reference>
<reference key="8">
<citation type="submission" date="2000-04" db="EMBL/GenBank/DDBJ databases">
<title>Expression of transcription factor Sp1 mRNA in mammalian cells.</title>
<authorList>
<person name="Nicolas M."/>
<person name="Noe V."/>
<person name="Ciudad C.J."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 1)</scope>
</reference>
<reference key="9">
<citation type="submission" date="2000-02" db="EMBL/GenBank/DDBJ databases">
<title>Sequencing of the 5' end of human transcription factor SP1 mRNA.</title>
<authorList>
<person name="Handschug K."/>
<person name="Huebner A."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 1-98 (ISOFORM 1)</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1988" name="Cell" volume="55" first="125" last="133">
<title>O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation.</title>
<authorList>
<person name="Jackson S.P."/>
<person name="Tjian R."/>
</authorList>
<dbReference type="PubMed" id="3139301"/>
<dbReference type="DOI" id="10.1016/0092-8674(88)90015-3"/>
</citation>
<scope>GLYCOSYLATION</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1988" name="Cell" volume="55" first="887" last="898">
<title>Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif.</title>
<authorList>
<person name="Courey A.J."/>
<person name="Tjian R."/>
</authorList>
<dbReference type="PubMed" id="3142690"/>
<dbReference type="DOI" id="10.1016/0092-8674(88)90144-4"/>
</citation>
<scope>TRANSACTIVATION DOMAINS</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="25564" last="25569">
<title>Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat.</title>
<authorList>
<person name="Wang L."/>
<person name="Mukherjee S."/>
<person name="Jia F."/>
<person name="Narayan O."/>
<person name="Zhao L.J."/>
</authorList>
<dbReference type="PubMed" id="7592727"/>
<dbReference type="DOI" id="10.1074/jbc.270.43.25564"/>
</citation>
<scope>INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION)</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="4417" last="4430">
<title>The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1.</title>
<authorList>
<person name="Parks C.L."/>
<person name="Shenk T."/>
</authorList>
<dbReference type="PubMed" id="8626793"/>
<dbReference type="DOI" id="10.1074/jbc.271.8.4417"/>
</citation>
<scope>IDENTIFICATION OF SEROTONIN 1A RECEPTOR PROMOTER BINDING SITES</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1997" name="Mol. Cell. Biol." volume="17" first="6472" last="6480">
<title>O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions.</title>
<authorList>
<person name="Roos M.D."/>
<person name="Su K."/>
<person name="Baker J.R."/>
<person name="Kudlow J.E."/>
</authorList>
<dbReference type="PubMed" id="9343410"/>
<dbReference type="DOI" id="10.1128/mcb.17.11.6472"/>
</citation>
<scope>GLYCOSYLATION AT SER-491</scope>
<scope>MUTAGENESIS OF SER-491</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1998" name="J. Mol. Biol." volume="275" first="187" last="195">
<title>The SV40 capsid protein VP3 cooperates with the cellular transcription factor Sp1 in DNA-binding and in regulating viral promoter activity.</title>
<authorList>
<person name="Gordon-Shaag A."/>
<person name="Ben-Nun-Shaul O."/>
<person name="Kasamatsu H."/>
<person name="Oppenheim A.B."/>
<person name="Oppenheim A."/>
</authorList>
<dbReference type="PubMed" id="9466902"/>
<dbReference type="DOI" id="10.1006/jmbi.1997.1461"/>
</citation>
<scope>INTERACTION WITH SV40 VP2/3 (MICROBIAL INFECTION)</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="19573" last="19580">
<title>Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene.</title>
<authorList>
<person name="Ding H."/>
<person name="Benotmane A.M."/>
<person name="Suske G."/>
<person name="Collen D."/>
<person name="Belayew A."/>
</authorList>
<dbReference type="PubMed" id="10391891"/>
<dbReference type="DOI" id="10.1074/jbc.274.28.19573"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH HLTF</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2000" name="Mol. Cell. Biochem." volume="210" first="131" last="142">
<title>A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening.</title>
<authorList>
<person name="Gunther M."/>
<person name="Laithier M."/>
<person name="Brison O."/>
</authorList>
<dbReference type="PubMed" id="10976766"/>
<dbReference type="DOI" id="10.1023/a:1007177623283"/>
</citation>
<scope>INTERACTION WITH ATF7IP; PHC2; POGZ AND HCFC1</scope>
<source>
<tissue>Colon</tissue>
</source>
</reference>
<reference key="18">
<citation type="journal article" date="2001" name="Proc. Natl. Acad. Sci. U.S.A." volume="98" first="6611" last="6616">
<title>O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability.</title>
<authorList>
<person name="Yang X."/>
<person name="Su K."/>
<person name="Roos M.D."/>
<person name="Chang Q."/>
<person name="Paterson A.J."/>
<person name="Kudlow J.E."/>
</authorList>
<dbReference type="PubMed" id="11371615"/>
<dbReference type="DOI" id="10.1073/pnas.111099998"/>
</citation>
<scope>GLYCOSYLATION AT SER-491</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-491</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="20631" last="20639">
<title>Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription.</title>
<authorList>
<person name="Milanini-Mongiat J."/>
<person name="Pouyssegur J."/>
<person name="Pages G."/>
</authorList>
<dbReference type="PubMed" id="11904305"/>
<dbReference type="DOI" id="10.1074/jbc.m201753200"/>
</citation>
<scope>PHOSPHORYLATION AT THR-453 AND THR-739</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF THR-355; THR-453 AND THR-739</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="26761" last="26768">
<title>POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1.</title>
<authorList>
<person name="Lee D.K."/>
<person name="Suh D."/>
<person name="Edenberg H.J."/>
<person name="Hur M.W."/>
</authorList>
<dbReference type="PubMed" id="12004059"/>
<dbReference type="DOI" id="10.1074/jbc.m202078200"/>
</citation>
<scope>INTERACTION WITH ZBTB7A</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2002" name="J. Virol." volume="76" first="5915" last="5924">
<title>Cellular transcription factor Sp1 recruits simian virus 40 capsid proteins to the viral packaging signal, ses.</title>
<authorList>
<person name="Gordon-Shaag A."/>
<person name="Ben-Nun-Shaul O."/>
<person name="Roitman V."/>
<person name="Yosef Y."/>
<person name="Oppenheim A."/>
</authorList>
<dbReference type="PubMed" id="12021324"/>
<dbReference type="DOI" id="10.1128/jvi.76.12.5915-5924.2002"/>
</citation>
<scope>INTERACTION WITH SV40 VP1 (MICROBIAL INFECTION)</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="36496" last="36504">
<title>Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.</title>
<authorList>
<person name="Di Padova M."/>
<person name="Bruno T."/>
<person name="De Nicola F."/>
<person name="Iezzi S."/>
<person name="D'Angelo C."/>
<person name="Gallo R."/>
<person name="Nicosia D."/>
<person name="Corbi N."/>
<person name="Biroccio A."/>
<person name="Floridi A."/>
<person name="Passananti C."/>
<person name="Fanciulli M."/>
</authorList>
<dbReference type="PubMed" id="12847090"/>
<dbReference type="DOI" id="10.1074/jbc.m306694200"/>
</citation>
<scope>INTERACTION WITH AATF</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="38068" last="38075">
<title>Interaction between the varicella zoster virus IE62 major transactivator and cellular transcription factor Sp1.</title>
<authorList>
<person name="Peng H."/>
<person name="He H."/>
<person name="Hay J."/>
<person name="Ruyechan W.T."/>
</authorList>
<dbReference type="PubMed" id="12855699"/>
<dbReference type="DOI" id="10.1074/jbc.m302259200"/>
</citation>
<scope>INTERACTION WITH VARICELLA-ZOSTER VIRUS IE62 PROTEIN (MICROBIAL INFECTION)</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="2377" last="2382">
<title>Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter.</title>
<authorList>
<person name="Bonello M.R."/>
<person name="Khachigian L.M."/>
</authorList>
<dbReference type="PubMed" id="14593115"/>
<dbReference type="DOI" id="10.1074/jbc.m308254200"/>
</citation>
<scope>PHOSPHORYLATION AT THR-453 AND THR-739</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF THR-453 AND THR-739</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="13928" last="13935">
<title>Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins.</title>
<authorList>
<person name="Ichimura T."/>
<person name="Watanabe S."/>
<person name="Sakamoto Y."/>
<person name="Aoto T."/>
<person name="Fujita N."/>
<person name="Nakao M."/>
</authorList>
<dbReference type="PubMed" id="15691849"/>
<dbReference type="DOI" id="10.1074/jbc.m413654200"/>
</citation>
<scope>INTERACTION WITH ATF7IP AND ATF7IP2</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2006" name="Cancer Res." volume="66" first="6579" last="6588">
<title>DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor.</title>
<authorList>
<person name="Chao C.H."/>
<person name="Chen C.M."/>
<person name="Cheng P.L."/>
<person name="Shih J.W."/>
<person name="Tsou A.P."/>
<person name="Lee Y.H."/>
</authorList>
<dbReference type="PubMed" id="16818630"/>
<dbReference type="DOI" id="10.1158/0008-5472.can-05-2415"/>
</citation>
<scope>INTERACTION WITH DDX3X</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="3642" last="3650">
<title>Insulin dynamically regulates calmodulin gene expression by sequential O-glycosylation and phosphorylation of SP1 and its subcellular compartmentalization in liver cells.</title>
<authorList>
<person name="Majumdar G."/>
<person name="Harrington A."/>
<person name="Hungerford J."/>
<person name="Martinez-Hernandez A."/>
<person name="Gerling I.C."/>
<person name="Raghow R."/>
<person name="Solomon S."/>
</authorList>
<dbReference type="PubMed" id="16332679"/>
<dbReference type="DOI" id="10.1074/jbc.m511223200"/>
</citation>
<scope>GLYCOSYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702</scope>
<scope>PHOSPHORYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702</scope>
<scope>INDUCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="4718" last="4725">
<title>HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion.</title>
<authorList>
<person name="Hsu M.C."/>
<person name="Chang H.C."/>
<person name="Hung W.C."/>
</authorList>
<dbReference type="PubMed" id="16377629"/>
<dbReference type="DOI" id="10.1074/jbc.m510937200"/>
</citation>
<scope>PHOSPHORYLATION AT THR-453 AND THR-739</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="5567" last="5574">
<title>Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription.</title>
<authorList>
<person name="Spengler M.L."/>
<person name="Brattain M.G."/>
</authorList>
<dbReference type="PubMed" id="16407261"/>
<dbReference type="DOI" id="10.1074/jbc.m600035200"/>
</citation>
<scope>SUMOYLATION AT LYS-16</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>MUTAGENESIS OF LYS-16; GLU-18 AND LYS-19</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2006" name="J. Mol. Biol." volume="364" first="897" last="908">
<title>Increased chromatin association of Sp1 in interphase cells by PP2A-mediated dephosphorylations.</title>
<authorList>
<person name="Vicart A."/>
<person name="Lefebvre T."/>
<person name="Imbert J."/>
<person name="Fernandez A."/>
<person name="Kahn-Perles B."/>
</authorList>
<dbReference type="PubMed" id="17049555"/>
<dbReference type="DOI" id="10.1016/j.jmb.2006.09.036"/>
</citation>
<scope>PHOSPHORYLATION AT SER-59 AND THR-681</scope>
<scope>DEPHOSPHORYLATION</scope>
<scope>GLYCOSYLATION</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-59; SER-220; THR-355; THR-453; THR-651; THR-681 AND THR-739</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2006" name="Mol. Cell. Biol." volume="26" first="1770" last="1785">
<title>Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription.</title>
<authorList>
<person name="Hung J.J."/>
<person name="Wang Y.T."/>
<person name="Chang W.C."/>
</authorList>
<dbReference type="PubMed" id="16478997"/>
<dbReference type="DOI" id="10.1128/mcb.26.5.1770-1785.2006"/>
</citation>
<scope>ACETYLATION AT LYS-703</scope>
<scope>INTERACTION WITH HDAC1; EP300 AND JUN</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF LYS-703</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2006" name="Mol. Cell. Biol." volume="26" first="6748" last="6761">
<title>Phosphatidylinositol 3-kinase/protein kinase Czeta-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated derepression of transcription of the luteinizing hormone receptor gene.</title>
<authorList>
<person name="Zhang Y."/>
<person name="Liao M."/>
<person name="Dufau M.L."/>
</authorList>
<dbReference type="PubMed" id="16943418"/>
<dbReference type="DOI" id="10.1128/mcb.00560-06"/>
</citation>
<scope>PHOSPHORYLATION AT SER-641</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-641</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2006" name="Mol. Cell. Biol." volume="26" first="8214" last="8214">
<authorList>
<person name="Zhang Y."/>
<person name="Liao M."/>
<person name="Dufau M.L."/>
</authorList>
</citation>
<scope>ERRATUM OF PUBMED:16943418</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2006" name="Nat. Biotechnol." volume="24" first="1285" last="1292">
<title>A probability-based approach for high-throughput protein phosphorylation analysis and site localization.</title>
<authorList>
<person name="Beausoleil S.A."/>
<person name="Villen J."/>
<person name="Gerber S.A."/>
<person name="Rush J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="16964243"/>
<dbReference type="DOI" id="10.1038/nbt1240"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="35">
<citation type="journal article" date="2007" name="Mol. Cancer Res." volume="5" first="1319" last="1330">
<title>Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia-mutated kinase.</title>
<authorList>
<person name="Olofsson B.A."/>
<person name="Kelly C.M."/>
<person name="Kim J."/>
<person name="Hornsby S.M."/>
<person name="Azizkhan-Clifford J."/>
</authorList>
<dbReference type="PubMed" id="18171990"/>
<dbReference type="DOI" id="10.1158/1541-7786.mcr-07-0374"/>
</citation>
<scope>PHOSPHORYLATION AT SER-101</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-101</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2008" name="Biochem. Biophys. Res. Commun." volume="372" first="713" last="718">
<title>Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1.</title>
<authorList>
<person name="Chung S.S."/>
<person name="Kim J.H."/>
<person name="Park H.S."/>
<person name="Choi H.H."/>
<person name="Lee K.W."/>
<person name="Cho Y.M."/>
<person name="Lee H.K."/>
<person name="Park K.S."/>
</authorList>
<dbReference type="PubMed" id="18513490"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2008.05.096"/>
</citation>
<scope>GLYCOSYLATION</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-612; THR-640; SER-641; SER-698 AND SER-702</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2008" name="Cell Cycle" volume="7" first="623" last="630">
<title>Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation.</title>
<authorList>
<person name="Spengler M.L."/>
<person name="Guo L.W."/>
<person name="Brattain M.G."/>
</authorList>
<dbReference type="PubMed" id="18239466"/>
<dbReference type="DOI" id="10.4161/cc.7.5.5402"/>
</citation>
<scope>PHOSPHORYLATION AT SER-7 AND SER-59</scope>
<scope>SUMOYLATION AT LYS-16</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
<scope>UBIQUITINATION</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-7; SER-59; SER-728 AND SER-732</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2008" name="Cell. Signal." volume="20" first="1795" last="1803">
<title>Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites.</title>
<authorList>
<person name="Iwahori S."/>
<person name="Yasui Y."/>
<person name="Kudoh A."/>
<person name="Sato Y."/>
<person name="Nakayama S."/>
<person name="Murata T."/>
<person name="Isomura H."/>
<person name="Tsurumi T."/>
</authorList>
<dbReference type="PubMed" id="18619531"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2008.06.007"/>
</citation>
<scope>PHOSPHORYLATION AT SER-101</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-36; SER-56; SER-81; SER-85; THR-98; SER-101; THR-250; SER-281; SER-291; SER-296; SER-313; SER-351; THR-394; THR-427 AND SER-431</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2008" name="Circ. Res." volume="102" first="38" last="51">
<title>Angiotensin II-inducible platelet-derived growth factor-D transcription requires specific Ser/Thr residues in the second zinc finger region of Sp1.</title>
<authorList>
<person name="Tan N.Y."/>
<person name="Midgley V.C."/>
<person name="Kavurma M.M."/>
<person name="Santiago F.S."/>
<person name="Luo X."/>
<person name="Peden R."/>
<person name="Fahmy R.G."/>
<person name="Berndt M.C."/>
<person name="Molloy M.P."/>
<person name="Khachigian L.M."/>
</authorList>
<dbReference type="PubMed" id="18258854"/>
<dbReference type="DOI" id="10.1161/circresaha.107.167395"/>
</citation>
<scope>PHOSPHORYLATION AT THR-668; SER-670 AND THR-681</scope>
<scope>MUTAGENESIS OF THR-668; SER-670 AND THR-681</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2008" name="Mol. Biol. Cell" volume="19" first="1139" last="1151">
<title>Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis.</title>
<authorList>
<person name="Chuang J.-Y."/>
<person name="Wang Y.-T."/>
<person name="Yeh S.-H."/>
<person name="Liu Y.-W."/>
<person name="Chang W.-C."/>
<person name="Hung J.-J."/>
</authorList>
<dbReference type="PubMed" id="18199680"/>
<dbReference type="DOI" id="10.1091/mbc.e07-09-0881"/>
</citation>
<scope>PHOSPHORYLATION AT SER-59 AND THR-278</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>MUTAGENESIS OF SER-59; SER-73; THR-117; THR-278 AND THR-739</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-651</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="42">
<citation type="journal article" date="2009" name="Biochem. Biophys. Res. Commun." volume="380" first="569" last="574">
<title>O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription factors.</title>
<authorList>
<person name="Lim K."/>
<person name="Chang H.I."/>
</authorList>
<dbReference type="PubMed" id="19285002"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2009.01.121"/>
</citation>
<scope>GLYCOSYLATION</scope>
<scope>INTERACTION WITH ELF1</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2009" name="Biochem. Biophys. Res. Commun." volume="382" first="593" last="597">
<title>O-GlcNAcylation of Sp1 interrupts Sp1 interaction with NF-Y.</title>
<authorList>
<person name="Lim K."/>
<person name="Chang H.I."/>
</authorList>
<dbReference type="PubMed" id="19302979"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2009.03.075"/>
</citation>
<scope>GLYCOSYLATION</scope>
<scope>INTERACTION WITH NFYA</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2009" name="J. Biol. Chem." volume="284" first="5165" last="5174">
<title>MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity.</title>
<authorList>
<person name="Liu L."/>
<person name="Ishihara K."/>
<person name="Ichimura T."/>
<person name="Fujita N."/>
<person name="Hino S."/>
<person name="Tomita S."/>
<person name="Watanabe S."/>
<person name="Saitoh N."/>
<person name="Ito T."/>
<person name="Nakao M."/>
</authorList>
<dbReference type="PubMed" id="19106100"/>
<dbReference type="DOI" id="10.1074/jbc.m807098200"/>
</citation>
<scope>INTERACTION WITH ATF7IP AND TBP</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2009" name="J. Virol." volume="83" first="3704" last="3718">
<title>O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.</title>
<authorList>
<person name="Jochmann R."/>
<person name="Thurau M."/>
<person name="Jung S."/>
<person name="Hofmann C."/>
<person name="Naschberger E."/>
<person name="Kremmer E."/>
<person name="Harrer T."/>
<person name="Miller M."/>
<person name="Schaft N."/>
<person name="Stuerzl M."/>
</authorList>
<dbReference type="PubMed" id="19193796"/>
<dbReference type="DOI" id="10.1128/jvi.01384-08"/>
</citation>
<scope>GLYCOSYLATION</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2009" name="Proc. Natl. Acad. Sci. U.S.A." volume="106" first="13826" last="13831">
<title>Human BAHD1 promotes heterochromatic gene silencing.</title>
<authorList>
<person name="Bierne H."/>
<person name="Tham T.N."/>
<person name="Batsche E."/>
<person name="Dumay A."/>
<person name="Leguillou M."/>
<person name="Kerneis-Golsteyn S."/>
<person name="Regnault B."/>
<person name="Seeler J.S."/>
<person name="Muchardt C."/>
<person name="Feunteun J."/>
<person name="Cossart P."/>
</authorList>
<dbReference type="PubMed" id="19666599"/>
<dbReference type="DOI" id="10.1073/pnas.0901259106"/>
</citation>
<scope>INTERACTION WITH BAHD1</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2010" name="FEBS J." volume="277" first="1202" last="1218">
<title>Snail associates with EGR-1 and SP-1 to upregulate transcriptional activation of p15INK4b.</title>
<authorList>
<person name="Hu C.T."/>
<person name="Chang T.Y."/>
<person name="Cheng C.C."/>
<person name="Liu C.S."/>
<person name="Wu J.R."/>
<person name="Li M.C."/>
<person name="Wu W.S."/>
</authorList>
<dbReference type="PubMed" id="20121949"/>
<dbReference type="DOI" id="10.1111/j.1742-4658.2009.07553.x"/>
</citation>
<scope>INTERACTION WITH EGR1</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2010" name="J. Cell. Biochem." volume="109" first="782" last="793">
<title>Transcriptional regulation of human FE65, a ligand of Alzheimer's disease amyloid precursor protein, by Sp1.</title>
<authorList>
<person name="Yu H.T."/>
<person name="Chan W.W."/>
<person name="Chai K.H."/>
<person name="Lee C.W."/>
<person name="Chang R.C."/>
<person name="Yu M.S."/>
<person name="McLoughlin D.M."/>
<person name="Miller C.C."/>
<person name="Lau K.F."/>
</authorList>
<dbReference type="PubMed" id="20091743"/>
<dbReference type="DOI" id="10.1002/jcb.22457"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2</scope>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 AND SER-7</scope>
<scope>CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS]</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="50">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2011" name="Cell. Mol. Life Sci." volume="68" first="1953" last="1968">
<title>Transforming growth factor-beta-inducible early response gene 1 is a novel substrate for atypical protein kinase Cs.</title>
<authorList>
<person name="Alemu E.A."/>
<person name="Sjoettem E."/>
<person name="Outzen H."/>
<person name="Larsen K.B."/>
<person name="Holm T."/>
<person name="Bjoerkoey G."/>
<person name="Johansen T."/>
</authorList>
<dbReference type="PubMed" id="20953893"/>
<dbReference type="DOI" id="10.1007/s00018-010-0541-1"/>
</citation>
<scope>PHOSPHORYLATION AT SER-702</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2011" name="Mol. Cell. Biol." volume="31" first="3723" last="3733">
<title>Cooperative transcriptional activation by Klf4, Meis2, and Pbx1.</title>
<authorList>
<person name="Bjerke G.A."/>
<person name="Hyman-Walsh C."/>
<person name="Wotton D."/>
</authorList>
<dbReference type="PubMed" id="21746878"/>
<dbReference type="DOI" id="10.1128/mcb.01456-10"/>
</citation>
<scope>INTERACTION WITH MEIS2 AND PBX1</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2011" name="Mol. Genet. Genomics" volume="285" first="57" last="65">
<title>Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8.</title>
<authorList>
<person name="Sachrajda I."/>
<person name="Ratajewski M."/>
</authorList>
<dbReference type="PubMed" id="21046154"/>
<dbReference type="DOI" id="10.1007/s00438-010-0586-8"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2</scope>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7</scope>
<scope>CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS]</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-7 AND SER-59</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="56">
<citation type="journal article" date="2014" name="Nat. Struct. Mol. Biol." volume="21" first="927" last="936">
<title>Uncovering global SUMOylation signaling networks in a site-specific manner.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="D'Souza R.C."/>
<person name="Yang B."/>
<person name="Verlaan-de Vries M."/>
<person name="Mann M."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25218447"/>
<dbReference type="DOI" id="10.1038/nsmb.2890"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2017" name="Nat. Struct. Mol. Biol." volume="24" first="325" last="336">
<title>Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="Lyon D."/>
<person name="Young C."/>
<person name="Jensen L.J."/>
<person name="Vertegaal A.C."/>
<person name="Nielsen M.L."/>
</authorList>
<dbReference type="PubMed" id="28112733"/>
<dbReference type="DOI" id="10.1038/nsmb.3366"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2019" name="Cell. Mol. Life Sci.">
<title>The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with valines and intron reservoirs.</title>
<authorList>
<person name="Piskacek M."/>
<person name="Havelka M."/>
<person name="Jendruchova K."/>
<person name="Knight A."/>
<person name="Keegan L.P."/>
</authorList>
<dbReference type="PubMed" id="31375868"/>
<dbReference type="DOI" id="10.1007/s00018-019-03251-w"/>
</citation>
<scope>9AATAD MOTIF</scope>
</reference>
<reference key="59">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="7801" last="7809">
<title>Structures of zinc finger domains from transcription factor Sp1. Insights into sequence-specific protein-DNA recognition.</title>
<authorList>
<person name="Narayan V.A."/>
<person name="Kriwacki R.W."/>
<person name="Caradonna J.P."/>
</authorList>
<dbReference type="PubMed" id="9065444"/>
<dbReference type="DOI" id="10.1074/jbc.272.12.7801"/>
</citation>
<scope>STRUCTURE BY NMR OF 654-684 AND 684-712</scope>
</reference>
<comment type="function">
<text evidence="12 13 15 17 18 23 26 28 30 31 32 33 34 36 37 39 43 45 47">Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Binds also the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component ARNTL/BMAL1 (PubMed:10391891, PubMed:11371615, PubMed:11904305, PubMed:14593115, PubMed:16377629, PubMed:16478997, PubMed:16943418, PubMed:17049555, PubMed:18171990, PubMed:18199680, PubMed:18239466, PubMed:18513490, PubMed:18619531, PubMed:19193796, PubMed:20091743, PubMed:21798247, PubMed:21046154). Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity).</text>
</comment>
<comment type="subunit">
<text evidence="12 13 15 16 19 21 24 28 29 38 40 41 42 44 46">Interacts with ATF7IP, ATF7IP2, BAHD1, POGZ, HCFC1, AATF and PHC2. Interacts with HLTF; the interaction may be required for basal transcriptional activity of HLTF. Interacts (deacetylated form) with EP300; the interaction enhances gene expression. Interacts with HDAC1 and JUN. Interacts with ELF1; the interaction is inhibited by glycosylation of SP1. Interaction with NFYA; the interaction is inhibited by glycosylation of SP1. Interacts with ATF7IP and TBP. Interacts with MEIS2 isoform 4 and PBX1 isoform PBX1a. Interacts with EGR1 (PubMed:10391891, PubMed:10976766, PubMed:12021324, PubMed:12847090, PubMed:12855699, PubMed:15691849, PubMed:16478997, PubMed:19106100, PubMed:19285002, PubMed:19302979, PubMed:19666599, PubMed:20121949, PubMed:21746878, PubMed:7592727, PubMed:9466902). Interacts with SMARCA4/BRG1. Interacts with RNF112 in an oxidative stress-regulated manner (By similarity). Interacts with ZBTB7A; ZBTB7A prevents the binding to GC-rich motifs in promoters and represses the transcriptional activity of SP1 (PubMed:12004059). Interacts with DDX3X; this interaction potentiates SP1-induced CDKN1A/WAF1/CIP1 transcription (PubMed:16818630).</text>
</comment>
<comment type="subunit">
<text evidence="22">(Microbial infection) Interacts with varicella-zoster virus IE62 protein.</text>
</comment>
<comment type="subunit">
<text evidence="20 51">(Microbial infection) Interacts with SV40 VP2/3 proteins. Interacts with SV40 major capsid protein VP1; this interaction leads to a cooperativity between the 2 proteins in DNA binding.</text>
</comment>
<comment type="subunit">
<text evidence="49">(Microbial infection) Interacts with HIV-1 Vpr; the interaction is inhibited by SP1 O-glycosylation.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-372428">
<id>Q9NY61</id>
<label>AATF</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-625922">
<id>Q8N726</id>
<label>CDKN2A</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-1752755">
<id>Q92988</id>
<label>DLX4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-448924">
<id>Q01094</id>
<label>E2F1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-765526">
<id>P32519</id>
<label>ELF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-447470">
<id>Q99814</id>
<label>EPAS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-78473">
<id>P03372</id>
<label>ESR1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-396176">
<id>P51610</id>
<label>HCFC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-301834">
<id>Q13547</id>
<label>HDAC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-447269">
<id>Q16665</id>
<label>HIF1A</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-1389509">
<id>Q13118</id>
<label>KLF10</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-447544">
<id>P01106</id>
<label>MYC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-389883">
<id>P16333</id>
<label>NCK1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-713786">
<id>Q8IXK0</id>
<label>PHC2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-1389308">
<id>Q7Z3K3</id>
<label>POGZ</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-624770">
<id>P14859</id>
<label>POU2F1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-743342">
<id>Q06455</id>
<label>RUNX1T1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-1054743">
<id>Q15459</id>
<label>SF3A1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-347263">
<id>Q13485</id>
<label>SMAD4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-465059">
<id>Q12772</id>
<label>SREBF2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-518675">
<id>P40763</id>
<label>STAT3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-3922312">
<id>Q9UL17</id>
<label>TBX21</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-366083">
<id>P04637</id>
<label>TP53</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-2515601">
<id>Q8N680</id>
<label>ZBTB2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-298336">
<id>P08047</id>
</interactant>
<interactant intactId="EBI-862337">
<id>P23708</id>
<label>Nfya</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>18</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
<text>Nuclear location is governed by glycosylated/phosphorylated states. Insulin promotes nuclear location, while glucagon favors cytoplasmic location.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P08047-1</id>
<name>1</name>
<name>Sp1a</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P08047-2</id>
<name>2</name>
<name>Sp1b</name>
<sequence type="described" ref="VSP_053934"/>
</isoform>
<isoform>
<id>P08047-3</id>
<name>3</name>
<name>Sp1c</name>
<sequence type="described" ref="VSP_053935"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="47">Up-regulated in adenocarcinomas of the stomach (at protein level). Isoform 3 is ubiquitously expressed at low levels.</text>
</comment>
<comment type="induction">
<text evidence="25">By insulin.</text>
</comment>
<comment type="domain">
<text evidence="48">The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.</text>
</comment>
<comment type="PTM">
<text evidence="18 23 25 26 30 31 32 33 34 35 37">Phosphorylated on multiple serine and threonine residues. Phosphorylation is coupled to ubiquitination, sumoylation and proteolytic processing. Phosphorylation on Ser-59 enhances proteolytic cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein degradation. Hyperphosphorylation on Ser-101 in response to DNA damage has no effect on transcriptional activity. MAPK1/MAPK3-mediated phosphorylation on Thr-453 and Thr-739 enhances VEGF transcription but, represses FGF2-triggered PDGFR-alpha transcription. Also implicated in the repression of RECK by ERBB2. Hyperphosphorylated on Thr-278 and Thr-739 during mitosis by MAPK8 shielding SP1 from degradation by the ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain by calmodulin-activated PKCzeta. Phosphorylation on Ser-641 by PKCzeta is critical for TSA-activated LHR gene expression through release of its repressor, p107. Phosphorylation on Thr-668, Ser-670 and Thr-681 is stimulated by angiotensin II via the AT1 receptor inducing increased binding to the PDGF-D promoter. This phosphorylation is increased in injured artey wall. Ser-59 and Thr-681 can both be dephosphorylated by PP2A during cell-cycle interphase. Dephosphorylation on Ser-59 leads to increased chromatin association during interphase and increases the transcriptional activity. On insulin stimulation, sequentially glycosylated and phosphorylated on several C-terminal serine and threonine residues.</text>
</comment>
<comment type="PTM">
<text evidence="28">Acetylated. Acetylation/deacetylation events affect transcriptional activity. Deacetylation leads to an increase in the expression the 12(s)-lipooxygenase gene though recruitment of p300 to the promoter.</text>
</comment>
<comment type="PTM">
<text evidence="34">Ubiquitinated. Ubiquitination occurs on the C-terminal proteolytically-cleaved peptide and is triggered by phosphorylation.</text>
</comment>
<comment type="PTM">
<text>Sumoylated with SUMO1. Sumoylation modulates proteolytic cleavage of the N-terminal repressor domain. Sumoylation levels are attenuated during tumorigenesis. Phosphorylation mediates SP1 desumoylation.</text>
</comment>
<comment type="PTM">
<text>Proteolytic cleavage in the N-terminal repressor domain is prevented by sumoylation. The C-terminal cleaved product is susceptible to degradation.</text>
</comment>
<comment type="PTM">
<text>O-glycosylated; Contains 8 N-acetylglucosamine side chains. Levels are controlled by insulin and the SP1 phosphorylation states. Insulin-mediated O-glycosylation locates SP1 to the nucleus, where it is sequentially deglycosylated and phosphorylated. O-glycosylation affects transcriptional activity through disrupting the interaction with a number of transcription factors including ELF1 and NFYA. Also inhibits interaction with the HIV1 promoter. Inhibited by peroxisomome proliferator receptor gamma (PPARgamma).</text>
</comment>
<comment type="miscellaneous">
<text>In the hepatoma cell line Hep-G2, SP1 precursor mRNA may undergo homotype trans-splicing leading to the duplication of exons 2 and 3.</text>
</comment>
<comment type="similarity">
<text evidence="53">Belongs to the Sp1 C2H2-type zinc-finger protein family.</text>
</comment>
<comment type="sequence caution" evidence="53">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAH43224" version="1"/>
</conflict>
<text>Extended N-terminus.</text>
</comment>
<dbReference type="EMBL" id="FN908228">
<property type="protein sequence ID" value="CBM42955.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC068889">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC073611">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471054">
<property type="protein sequence ID" value="EAW96699.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC043224">
<property type="protein sequence ID" value="AAH43224.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC062539">
<property type="protein sequence ID" value="AAH62539.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF252284">
<property type="protein sequence ID" value="AAF67726.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB039286">
<property type="protein sequence ID" value="BAB13476.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="J03133">
<property type="protein sequence ID" value="AAA61154.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF255682">
<property type="protein sequence ID" value="AAF78781.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AJ272134">
<property type="protein sequence ID" value="CAB75345.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS44898.1">
<molecule id="P08047-2"/>
</dbReference>
<dbReference type="CCDS" id="CCDS8857.1">
<molecule id="P08047-1"/>
</dbReference>
<dbReference type="PIR" id="A29635">
<property type="entry name" value="A29635"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001238754.1">
<molecule id="P08047-3"/>
<property type="nucleotide sequence ID" value="NM_001251825.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_003100.1">
<molecule id="P08047-2"/>
<property type="nucleotide sequence ID" value="NM_003109.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_612482.2">
<molecule id="P08047-1"/>
<property type="nucleotide sequence ID" value="NM_138473.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011536998.1">
<property type="nucleotide sequence ID" value="XM_011538696.2"/>
</dbReference>
<dbReference type="PDB" id="1SP1">
<property type="method" value="NMR"/>
<property type="chains" value="A=684-712"/>
</dbReference>
<dbReference type="PDB" id="1SP2">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="1VA1">
<property type="method" value="NMR"/>
<property type="chains" value="A=619-654"/>
</dbReference>
<dbReference type="PDB" id="1VA2">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="1VA3">
<property type="method" value="NMR"/>
<property type="chains" value="A=684-712"/>
</dbReference>
<dbReference type="PDB" id="6PV0">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="6PV1">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="6PV2">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="6PV3">
<property type="method" value="NMR"/>
<property type="chains" value="A=655-684"/>
</dbReference>
<dbReference type="PDB" id="6UCO">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDB" id="6UCP">
<property type="method" value="NMR"/>
<property type="chains" value="A=654-684"/>
</dbReference>
<dbReference type="PDBsum" id="1SP1"/>
<dbReference type="PDBsum" id="1SP2"/>
<dbReference type="PDBsum" id="1VA1"/>
<dbReference type="PDBsum" id="1VA2"/>
<dbReference type="PDBsum" id="1VA3"/>
<dbReference type="PDBsum" id="6PV0"/>
<dbReference type="PDBsum" id="6PV1"/>
<dbReference type="PDBsum" id="6PV2"/>
<dbReference type="PDBsum" id="6PV3"/>
<dbReference type="PDBsum" id="6UCO"/>
<dbReference type="PDBsum" id="6UCP"/>
<dbReference type="BMRB" id="P08047"/>
<dbReference type="SMR" id="P08047"/>
<dbReference type="BioGRID" id="112550">
<property type="interactions" value="246"/>
</dbReference>
<dbReference type="CORUM" id="P08047"/>
<dbReference type="DIP" id="DIP-36N"/>
<dbReference type="ELM" id="P08047"/>
<dbReference type="IntAct" id="P08047">
<property type="interactions" value="73"/>
</dbReference>
<dbReference type="MINT" id="P08047"/>
<dbReference type="STRING" id="9606.ENSP00000329357"/>
<dbReference type="ChEMBL" id="CHEMBL6103"/>
<dbReference type="GlyConnect" id="605">
<property type="glycosylation" value="1 O-Linked glycan"/>
</dbReference>
<dbReference type="GlyGen" id="P08047">
<property type="glycosylation" value="11 sites, 1 O-linked glycan (5 sites)"/>
</dbReference>
<dbReference type="iPTMnet" id="P08047"/>
<dbReference type="PhosphoSitePlus" id="P08047"/>
<dbReference type="UniCarbKB" id="P08047"/>
<dbReference type="BioMuta" id="SP1"/>
<dbReference type="DMDM" id="13638437"/>
<dbReference type="EPD" id="P08047"/>
<dbReference type="jPOST" id="P08047"/>
<dbReference type="MassIVE" id="P08047"/>
<dbReference type="MaxQB" id="P08047"/>
<dbReference type="PaxDb" id="P08047"/>
<dbReference type="PeptideAtlas" id="P08047"/>
<dbReference type="PRIDE" id="P08047"/>
<dbReference type="ProteomicsDB" id="33987"/>
<dbReference type="ProteomicsDB" id="52061">
<molecule id="P08047-1"/>
</dbReference>
<dbReference type="Antibodypedia" id="892">
<property type="antibodies" value="1025 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000327443">
<molecule id="P08047-1"/>
<property type="protein sequence ID" value="ENSP00000329357"/>
<property type="gene ID" value="ENSG00000185591"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000426431">
<molecule id="P08047-2"/>
<property type="protein sequence ID" value="ENSP00000404263"/>
<property type="gene ID" value="ENSG00000185591"/>
</dbReference>
<dbReference type="GeneID" id="6667"/>
<dbReference type="KEGG" id="hsa:6667"/>
<dbReference type="UCSC" id="uc001scw.4">
<molecule id="P08047-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="6667"/>
<dbReference type="DisGeNET" id="6667"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000185591.9"/>
<dbReference type="GeneCards" id="SP1"/>
<dbReference type="HGNC" id="HGNC:11205">
<property type="gene designation" value="SP1"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000185591">
<property type="expression patterns" value="Low tissue specificity"/>
</dbReference>
<dbReference type="MIM" id="189906">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P08047"/>
<dbReference type="OpenTargets" id="ENSG00000185591"/>
<dbReference type="PharmGKB" id="PA36042"/>
<dbReference type="eggNOG" id="KOG1721">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00940000157804"/>
<dbReference type="HOGENOM" id="CLU_019688_2_0_1"/>
<dbReference type="InParanoid" id="P08047"/>
<dbReference type="KO" id="K04684"/>
<dbReference type="OMA" id="EACTCPM"/>
<dbReference type="OrthoDB" id="1085860at2759"/>
<dbReference type="PhylomeDB" id="P08047"/>
<dbReference type="TreeFam" id="TF350150"/>
<dbReference type="PathwayCommons" id="P08047"/>
<dbReference type="Reactome" id="R-HSA-1989781">
<property type="pathway name" value="PPARA activates gene expression"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2173796">
<property type="pathway name" value="SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2426168">
<property type="pathway name" value="Activation of gene expression by SREBF (SREBP)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2559585">
<property type="pathway name" value="Oncogene Induced Senescence"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6807505">
<property type="pathway name" value="RNA polymerase II transcribes snRNA genes"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9018519">
<property type="pathway name" value="Estrogen-dependent gene expression"/>
</dbReference>
<dbReference type="SignaLink" id="P08047"/>
<dbReference type="SIGNOR" id="P08047"/>
<dbReference type="BioGRID-ORCS" id="6667">
<property type="hits" value="119 hits in 897 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="SP1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P08047"/>
<dbReference type="GeneWiki" id="Sp1_transcription_factor"/>
<dbReference type="GenomeRNAi" id="6667"/>
<dbReference type="Pharos" id="P08047">
<property type="development level" value="Tbio"/>
</dbReference>
<dbReference type="PRO" id="PR:P08047"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 12"/>
</dbReference>
<dbReference type="RNAct" id="P08047">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000185591">
<property type="expression patterns" value="Expressed in nipple and 221 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P08047">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P08047">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0000790">
<property type="term" value="C:nuclear chromatin"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005719">
<property type="term" value="C:nuclear euchromatin"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ParkinsonsUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0032993">
<property type="term" value="C:protein-DNA complex"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0017053">
<property type="term" value="C:transcription repressor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0043425">
<property type="term" value="F:bHLH transcription factor binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0000987">
<property type="term" value="F:cis-regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0003677">
<property type="term" value="F:DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001228">
<property type="term" value="F:DNA-binding transcription activator activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0003700">
<property type="term" value="F:DNA-binding transcription factor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000981">
<property type="term" value="F:DNA-binding transcription factor activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000247"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:0003690">
<property type="term" value="F:double-stranded DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035035">
<property type="term" value="F:histone acetyltransferase binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042826">
<property type="term" value="F:histone deacetylase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071837">
<property type="term" value="F:HMG box domain binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046872">
<property type="term" value="F:metal ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0008022">
<property type="term" value="F:protein C-terminus binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070491">
<property type="term" value="F:repressing transcription factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0000978">
<property type="term" value="F:RNA polymerase II cis-regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001103">
<property type="term" value="F:RNA polymerase II repressing transcription factor binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0000977">
<property type="term" value="F:RNA polymerase II transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043565">
<property type="term" value="F:sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1990837">
<property type="term" value="F:sequence-specific double-stranded DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008134">
<property type="term" value="F:transcription factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000976">
<property type="term" value="F:transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032869">
<property type="term" value="P:cellular response to insulin stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043923">
<property type="term" value="P:positive regulation by host of viral transcription"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902004">
<property type="term" value="P:positive regulation of amyloid-beta formation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045766">
<property type="term" value="P:positive regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043536">
<property type="term" value="P:positive regulation of blood vessel endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010628">
<property type="term" value="P:positive regulation of gene expression"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1904828">
<property type="term" value="P:positive regulation of hydrogen sulfide biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045944">
<property type="term" value="P:positive regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1905564">
<property type="term" value="P:positive regulation of vascular endothelial cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045540">
<property type="term" value="P:regulation of cholesterol biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006355">
<property type="term" value="P:regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0033194">
<property type="term" value="P:response to hydroperoxide"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048511">
<property type="term" value="P:rhythmic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0042795">
<property type="term" value="P:snRNA transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0016032">
<property type="term" value="P:viral process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="DisProt" id="DP00378"/>
<dbReference type="IDEAL" id="IID00266"/>
<dbReference type="InterPro" id="IPR036236">
<property type="entry name" value="Znf_C2H2_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013087">
<property type="entry name" value="Znf_C2H2_type"/>
</dbReference>
<dbReference type="Pfam" id="PF00096">
<property type="entry name" value="zf-C2H2"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00355">
<property type="entry name" value="ZnF_C2H2"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF57667">
<property type="entry name" value="SSF57667"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00028">
<property type="entry name" value="ZINC_FINGER_C2H2_1"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="PROSITE" id="PS50157">
<property type="entry name" value="ZINC_FINGER_C2H2_2"/>
<property type="match status" value="3"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0007">Acetylation</keyword>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0090">Biological rhythms</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0238">DNA-binding</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0945">Host-virus interaction</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0678">Repressor</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0862">Zinc</keyword>
<keyword id="KW-0863">Zinc-finger</keyword>
<feature type="initiator methionine" description="Removed" evidence="7 8">
<location>
<position position="1"/>
</location>
</feature>
<feature type="chain" description="Transcription factor Sp1" id="PRO_0000047137">
<location>
<begin position="2"/>
<end position="785"/>
</location>
</feature>
<feature type="zinc finger region" description="C2H2-type 1" evidence="14">
<location>
<begin position="626"/>
<end position="650"/>
</location>
</feature>
<feature type="zinc finger region" description="C2H2-type 2" evidence="14">
<location>
<begin position="656"/>
<end position="680"/>
</location>
</feature>
<feature type="zinc finger region" description="C2H2-type 3" evidence="14">
<location>
<begin position="686"/>
<end position="708"/>
</location>
</feature>
<feature type="region of interest" description="Repressor domain">
<location>
<begin position="2"/>
<end position="82"/>
</location>
</feature>
<feature type="region of interest" description="Transactivation domain A (Gln-rich)">
<location>
<begin position="146"/>
<end position="251"/>
</location>
</feature>
<feature type="region of interest" description="Transactivation domain B (Gln-rich)">
<location>
<begin position="261"/>
<end position="495"/>
</location>
</feature>
<feature type="region of interest" description="Transactivation domain C (highly charged)">
<location>
<begin position="496"/>
<end position="610"/>
</location>
</feature>
<feature type="region of interest" description="VZV IE62-binding">
<location>
<begin position="619"/>
<end position="785"/>
</location>
</feature>
<feature type="region of interest" description="Domain D">
<location>
<begin position="708"/>
<end position="785"/>
</location>
</feature>
<feature type="short sequence motif" description="9aaTAD" evidence="48">
<location>
<begin position="462"/>
<end position="470"/>
</location>
</feature>
<feature type="compositionally biased region" description="Ser/Thr-rich">
<location>
<begin position="36"/>
<end position="143"/>
</location>
</feature>
<feature type="compositionally biased region" description="Ser/Thr-rich">
<location>
<begin position="271"/>
<end position="379"/>
</location>
</feature>
<feature type="site" description="Cleavage" evidence="53">
<location>
<begin position="63"/>
<end position="64"/>
</location>
</feature>
<feature type="modified residue" description="N-acetylserine" evidence="7 8">
<location>
<position position="2"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="7 9">
<location>
<position position="2"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="7 8 9 34">
<location>
<position position="7"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5 9 31 33 34">
<location>
<position position="59"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATM" evidence="32 37">
<location>
<position position="101"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by MAPK8" evidence="54">
<location>
<position position="278"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by MAPK1 and MAPK3" evidence="18 23 26">
<location>
<position position="453"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; alternate" evidence="25">
<location>
<position position="612"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; alternate" evidence="25">
<location>
<position position="640"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKC/PRKCZ; alternate" evidence="25 30">
<location>
<position position="641"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by PKC/PRKCZ" evidence="6">
<location>
<position position="651"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="35">
<location>
<position position="668"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by PKC/PRKCZ" evidence="35">
<location>
<position position="670"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by PKC/PRKCZ" evidence="31 35">
<location>
<position position="681"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; alternate" evidence="25">
<location>
<position position="698"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; alternate" evidence="25 55">
<location>
<position position="702"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine" evidence="28">
<location>
<position position="703"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by MAPK1, MAPK3 and MAPK8" evidence="18 23 26">
<location>
<position position="739"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine" evidence="17 50">
<location>
<position position="491"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="25">
<location>
<position position="612"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) threonine; alternate" evidence="25">
<location>
<position position="640"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="25">
<location>
<position position="641"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="25">
<location>
<position position="698"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="25">
<location>
<position position="702"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate">
<location>
<position position="16"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="10 11">
<location>
<position position="16"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_053934" evidence="53">
<location>
<begin position="1"/>
<end position="7"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_053935" evidence="52">
<location>
<begin position="54"/>
<end position="101"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs3741665." id="VAR_019971">
<original>T</original>
<variation>A</variation>
<location>
<position position="737"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increase in protein stability. No change in sumoylation." evidence="34">
<original>S</original>
<variation>A</variation>
<location>
<position position="7"/>
</location>
</feature>
<feature type="mutagenesis site" description="Enhanced transcriptional activity.">
<original>V</original>
<variation>R</variation>
<location>
<position position="15"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of sumoylation. No cleavage and reduced transcriptional activity." evidence="27">
<original>K</original>
<variation>R</variation>
<location>
<position position="16"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of sumoylation. Increased cleavage and enhanced transcriptional activity." evidence="27">
<original>E</original>
<variation>A</variation>
<location>
<position position="18"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on sumoylation nor on proteolytic cleavage." evidence="27">
<original>K</original>
<variation>R</variation>
<location>
<position position="19"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="36"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="56"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation. No effect on activated MAPK8-mediated phosphorylation. Similar loss of phosphorylation as by dephosphorylation by PP2AC. Reduced proteolytic processing." evidence="31 33 34">
<original>S</original>
<variation>A</variation>
<location>
<position position="59"/>
</location>
</feature>
<feature type="mutagenesis site" description="Some association with chromatin, increased phosphorylation levels and decreased glycosylation." evidence="31 33 34">
<original>S</original>
<variation>E</variation>
<location>
<position position="59"/>
</location>
</feature>
<feature type="mutagenesis site" description="Little effect on activated MAPK8-mediated phosphorylation." evidence="33">
<original>S</original>
<variation>A</variation>
<location>
<position position="73"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="81"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="85"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>T</original>
<variation>A</variation>
<location>
<position position="98"/>
</location>
</feature>
<feature type="mutagenesis site" description="Significant reduction of phosphorylation on DNA damage." evidence="32 37">
<original>S</original>
<variation>A</variation>
<location>
<position position="101"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increase in phosphorylation on DNA damage." evidence="32 37">
<original>S</original>
<variation>D</variation>
<location>
<position position="101"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on activated MAPK8-mediated phosphorylation." evidence="33">
<original>T</original>
<variation>A</variation>
<location>
<position position="117"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on dephosphorylation by PP2A." evidence="31">
<original>S</original>
<variation>A</variation>
<location>
<position position="220"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>T</original>
<variation>A</variation>
<location>
<position position="250"/>
</location>
</feature>
<feature type="mutagenesis site" description="Almost complete abolition of activated MAPK8-mediated phosphorylation and 40% reduction in protein levels during mitosis. Protein levels reduced by 70% during mitosis; when associated with A-739." evidence="33">
<original>T</original>
<variation>A</variation>
<location>
<position position="278"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased protein stability during mitosis; when associated with D-739." evidence="33">
<original>T</original>
<variation>D</variation>
<location>
<position position="278"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="281"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="291"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="296"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="313"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="351"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on dephosphorylation by PP2A." evidence="18 31">
<original>T</original>
<variation>A</variation>
<location>
<position position="355"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>T</original>
<variation>A</variation>
<location>
<position position="394"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>T</original>
<variation>A</variation>
<location>
<position position="427"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on phosphorylation on DNA damage." evidence="37">
<original>S</original>
<variation>A</variation>
<location>
<position position="431"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes MAPK-mediated phosphorylation, 50% reduction in MAPK1/MAPK3-mediated activity on VEGF promoter and no effect on dephosphorylation by PP2A. Greatly reduced MAPK1-mediated activity on VEGF promoter; when associated with A-739." evidence="18 23 31">
<original>T</original>
<variation>A</variation>
<location>
<position position="453"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of O-glycosylation. Increase in transcriptional activity." evidence="17 50">
<original>S</original>
<variation>A</variation>
<location>
<position position="491"/>
</location>
</feature>
<feature type="mutagenesis site" description="Diminished glycosylation. Inhibits transcriptional activity; when associated with A-640; A-641; A-698 and A-702." evidence="36">
<original>S</original>
<variation>A</variation>
<location>
<position position="612"/>
</location>
</feature>
<feature type="mutagenesis site" description="Diminished glycosylation. Inhibits transcriptional activity; when associated with A-612; A-641; A-698 and A-702." evidence="36">
<original>T</original>
<variation>A</variation>
<location>
<position position="640"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PRKCzeta-mediated phosphorylation. Diminished glycosylation. Inhibits transcriptional activity; when associated with A-612; A-640; A-641 and A-702." evidence="30 36">
<original>S</original>
<variation>A</variation>
<location>
<position position="641"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on dephosphorylation by PP2A." evidence="31">
<original>T</original>
<variation>A</variation>
<location>
<position position="651"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PRKCzeta-mediated but not PKCdelta-mediated phosphorylation. No effect on DNA binding; when associated with A-670 and A-681." evidence="35">
<original>T</original>
<variation>A</variation>
<location>
<position position="668"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PRKCzeta-mediated but not PKCdelta-mediated phosphorylation. No effect on DNA binding; when associated with A-668 and A-681." evidence="35">
<original>S</original>
<variation>A</variation>
<location>
<position position="670"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes PRKCzeta-mediated but not PKCdelta-mediated phosphorylation. Some effect on dephosphorylation by PP2A. No effect on DNA binding; when associated with A-668 and A-681." evidence="31 35">
<original>T</original>
<variation>A</variation>
<location>
<position position="681"/>
</location>
</feature>
<feature type="mutagenesis site" description="Diminished glycosylation. Inhibits transcriptional activity; when associated with A-612; A-640; A-641 and A-702." evidence="36">
<original>S</original>
<variation>A</variation>
<location>
<position position="698"/>
</location>
</feature>
<feature type="mutagenesis site" description="Diminished glycosylation. Inhibits transcriptional activity; when associated with A-612; A-640; A-641 and A-698." evidence="36">
<original>S</original>
<variation>A</variation>
<location>
<position position="702"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes acetylation. Increases recruitment of p300 to the promoter and enhances gene transcription." evidence="28">
<original>K</original>
<variation>A</variation>
<location>
<position position="703"/>
</location>
</feature>
<feature type="mutagenesis site" description="Exhibits attenuated endoproteolytic cleavage; when associated with A-732." evidence="34">
<original>S</original>
<variation>A</variation>
<location>
<position position="728"/>
</location>
</feature>
<feature type="mutagenesis site" description="Exhibits attenuated endoproteolytic cleavage; when associated with A-728." evidence="34">
<original>S</original>
<variation>A</variation>
<location>
<position position="732"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes MAPK-mediated phosphorylation. 50% reduction in MAPK1/MAPK3-mediated activity on VEGF promoter, 40% reduction in protein levels during mitosis and no effect on dephosphorylation by PP2A. Greatly reduced MAPK1-mediated activity on VEGF promoter; when associated with A-453. Protein levels during mitosis reduced by 70%; when associated with A-278." evidence="18 23 31 33">
<original>T</original>
<variation>A</variation>
<location>
<position position="739"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased protein stability during mitosis; when associated with D-278." evidence="18 23 31 33">
<original>T</original>
<variation>D</variation>
<location>
<position position="739"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AA sequence." ref="7" evidence="53">
<original>D</original>
<variation>G</variation>
<location>
<position position="366"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AA sequence." ref="7" evidence="53">
<original>S</original>
<variation>F</variation>
<location>
<position position="670"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="620"/>
<end position="622"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="636"/>
<end position="638"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="640"/>
<end position="651"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="661"/>
<end position="663"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="666"/>
<end position="668"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="670"/>
<end position="677"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="678"/>
<end position="680"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="689"/>
<end position="692"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="699"/>
<end position="706"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="707"/>
<end position="709"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1SP1"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1SP2"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1VA1"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1VA2"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="16964243"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25218447"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="28112733"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="O89090"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q01714"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00042"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10391891"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10976766"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11371615"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11904305"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12004059"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12021324"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12847090"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12855699"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14593115"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15691849"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16332679"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16377629"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16407261"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16478997"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16818630"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16943418"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17049555"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18171990"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18199680"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18239466"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18258854"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18513490"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18619531"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19106100"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19193796"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19285002"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19302979"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19666599"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20091743"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20121949"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21046154"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21746878"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21798247"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="31375868"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7592727"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9343410"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9466902"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="21798247"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000305"/>
<evidence key="54" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18199680"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="20953893"/>
</source>
</evidence>
<sequence length="785" mass="80693" checksum="43893DBF6518B9EA" modified="2001-04-27" version="3">MSDQDHSMDEMTAVVKIEKGVGGNNGGNGNGGGAFSQARSSSTGSSSSTGGGGQESQPSPLALLAATCSRIESPNENSNNSQGPSQSGGTGELDLTATQLSQGANGWQIISSSSGATPTSKEQSGSSTNGSNGSESSKNRTVSGGQYVVAAAPNLQNQQVLTGLPGVMPNIQYQVIPQFQTVDGQQLQFAATGAQVQQDGSGQIQIIPGANQQIITNRGSGGNIIAAMPNLLQQAVPLQGLANNVLSGQTQYVTNVPVALNGNITLLPVNSVSAATLTPSSQAVTISSSGSQESGSQPVTSGTTISSASLVSSQASSSSFFTNANSYSTTTTTSNMGIMNFTTSGSSGTNSQGQTPQRVSGLQGSDALNIQQNQTSGGSLQAGQQKEGEQNQQTQQQQILIQPQLVQGGQALQALQAAPLSGQTFTTQAISQETLQNLQLQAVPNSGPIIIRTPTVGPNGQVSWQTLQLQNLQVQNPQAQTITLAPMQGVSLGQTSSSNTTLTPIASAASIPAGTVTVNAAQLSSMPGLQTINLSALGTSGIQVHPIQGLPLAIANAPGDHGAQLGLHGAGGDGIHDDTAGGEEGENSPDAQPQAGRRTRREACTCPYCKDSEGRGSGDPGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFTRSDELQRHKRTHTGEKKFACPECPKRFMRSDHLSKHIKTHQNKKGGPGVALSVGTLPLDSGAGSEGSGTATPSALITTNMVAMEAICPEGIARLANSGINVMQVADLQSINISGNGF</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

